Premium
Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab
Author(s) -
Nosaka Kisato,
Kusumoto Shigeru,
Nakano Nobuaki,
Choi Ilseung,
Yoshimitsu Makoto,
Imaizumi Yoshitaka,
Hidaka Michihiro,
Sasaki Hidenori,
Makiyama Junya,
Ohtsuka Eiichi,
Jo Tatsuro,
Ogata Masao,
Ito Asahi,
Yonekura Kentaro,
Tatetsu Hiro,
Kato Takeharu,
Kawakita Toshiro,
Suehiro Youko,
Ishitsuka Kenji,
Iida Shinsuke,
Matsutani Takaji,
Utsunomiya Atae,
Ueda Ryuzo,
Ishida Takashi
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17895
Subject(s) - peripheral blood mononuclear cell , immunology , immune system , antibody , medicine , hazard ratio , biology , confidence interval , biochemistry , in vitro
Summary ‘Monitoring of immune responses following mogamulizumab‐containing treatment in patients with adult T‐cell leukaemia–lymphoma (ATL)’ (MIMOGA) is a multicentre prospective clinical study (UMIN8696). In the MIMOGA study, we found that a lower percentage of CD2 − CD19 + B cells in peripheral blood mononuclear cells (PBMC) was a significant unfavourable prognostic factor for overall survival (OS). Accordingly, we then analysed the immunoglobulin G (IgG) heavy‐chain repertoire in PBMC by high‐throughput sequencing. Of the 101 patients enrolled in the MIMOGA study, for 81 a sufficient amount of PBMC RNA was available for repertoire sequencing analysis. Peripheral IgG B cells in patients with ATL had a restricted repertoire relative to those in healthy individuals. There was a significant positive correlation between the Shannon–Weaver diversity index (SWDI) for the IgG repertoire and proportions of B cells in the PBMC of the patients. Multivariate analysis identified two variables significantly affecting OS: a higher serum soluble interleukin‐2 receptor level, and a lower SWDI for the IgG repertoire [hazard ratio, 2·124; 95% confidence interval, 1·114–4·049; n = 44]. The present study documents the importance of humoral immune responses in patients receiving mogamulizumab‐containing treatment. Further investigation of strategies to enhance humoral immune responses in patients with ATL is warranted.